This map shows the geographic impact of Hugh Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh Lin more than expected).
This network shows the impact of papers produced by Hugh Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh Lin. The network helps show where Hugh Lin may publish in the future.
Co-authorship network of co-authors of Hugh Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Hugh Lin.
A scholar is included among the top collaborators of Hugh Lin based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Hugh Lin. Hugh Lin is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Wells, John A., Charles C. Wykoff, Jeffrey R. Willis, et al.. (2021). Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials. Investigative Ophthalmology & Visual Science. 62(8). 1037–1037.2 indexed citations
3.
Guymer, Robyn H., Carlos Quezada-Ruiz, Jeffrey R. Willis, et al.. (2021). Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design. Investigative Ophthalmology & Visual Science. 62(8). 429–429.
4.
Khanani, Arshad M., Jeffrey S. Heier, Carlos Quezada-Ruiz, et al.. (2021). Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials. Investigative Ophthalmology & Visual Science. 62(8). 428–428.5 indexed citations
5.
Eter, Nicole, Rishi P. Singh, Francis Abreu, et al.. (2021). YOSEMITE and RHINE. SHILAP Revista de lepidopterología. 2(1). 100111–100111.43 indexed citations
6.
Khanani, Arshad M., Robyn H. Guymer, Karen Basu, et al.. (2021). TENAYA and LUCERNE. SHILAP Revista de lepidopterología. 1(4). 100076–100076.55 indexed citations
7.
Chakravarthy, Usha, Richard Foxton, Sabine Uhles, et al.. (2020). Sustained Vessel Stabilization Through Targeting Angiopoietin-2 (Ang-2) With Faricimab, a Bispecific Antibody Neutralizing Both Ang-2 and Vascular Endothelial Growth Factor A (VEGF-A). Investigative Ophthalmology & Visual Science. 61(7). 5126–5126.1 indexed citations
8.
Danzig, Carl J., et al.. (2020). Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial. 61(7). 1160–1160.1 indexed citations
Wakshull, Eric, et al.. (2018). Analysis of the serum and aqueous humor levels of IL-6 in patients with neovascular (wet) age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor A monotherapy. Investigative Ophthalmology & Visual Science. 59(9). 1456–1456.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.